About RX MT2 — Melanotan 2 Research Digest Editorial Mission
About This Site
RX MT2 is a reading room for the peer-reviewed literature on Melanotan 2 (MT-II). The compound's research record runs across four decades — tanning pharmacology, erectile-function trials, central appetite circuitry, neuroprotection, and a widening pharmacovigilance file — and this site's work is to organize that record in plain language, with every quantitative claim traced to its source.
What that means in practice: the site reads and summarizes published science; it is not a clinic and keeps no clinician on staff; it offers no medical guidance; and it makes, stocks, and sells nothing. The 'RX' in the name is a stance, not a storefront — it frames the site as a room you read the research in, not a pharmaceutical service. There is no prescription counter, no consultation, no treatment on offer. The literature summarized here comes from PubMed-indexed journals, clinical-trial records, and peer-reviewed pharmacovigilance reports, linked to primary sources throughout.
What This Site Covers
The Melanotan 2 literature is scientifically interesting for reasons beyond the compound's most publicized application. The serendipitous discovery that an alpha-MSH analog could produce erections in human subjects — documented in Hadley's 2005 historical account [18] — initiated a research program in central melanocortin pharmacology that ultimately contributed to the development of bremelanotide (PT-141), the first approved drug for hypoactive sexual desire disorder in premenopausal women.
The compound's receptor pharmacology is also the starting point for understanding appetite regulation through the melanocortinergic system, a pathway with implications for metabolic disease. And the pharmacovigilance record — including documented cases of renal infarction, melanoma, and priapism — provides important context for understanding the risks associated with unregulated synthetic peptide use.
This site covers the Melanotan 2 mechanism of action, the clinical trial record, the MT2 dosage protocols studied in research, the Melanotan 2 side effects documented in studies, and the frequently asked questions about the compound. The published references list every source cited across the site.
We do not cover commercial sources, sourcing guides, or product recommendations. Negative terms like 'buy Melanotan 2,' 'Melanotan 2 for sale,' and vendor comparisons are outside this site's editorial scope.
Editorial Standards
Every quantitative claim on this site is attributed to a specific citation in the references list. No finding is presented without a source. Where the research record is sparse or conflicting, we note it. Where adverse events are documented only in case reports and not confirmed in controlled trials, we say so.
The compound described here — MT-II — is not approved for human use by any regulatory authority. We do not describe it as safe. We do not recommend doses. We describe what was administered to which species at which dose in which study, and what was measured.
This is what a plainly kept reading room looks like: the primary sources, rendered in plain language, without a vendor's marketing frame or the overcautious hedging of an institution minding its liability.